Emmaus Life Sciences Inc - EMMA stock
OTC Market: EMMA
Emmaus Life Sciences, Inc. is a biopharmaceutical company that operates in the commercial-stage, focusing on the discovery, development, marketing, and sale of treatments and therapies primarily targeting rare and orphan diseases in the United States and internationally; its primary candidate is Endari, an L-glutamine oral powder designed to reduce acute complications in adult and pediatric patients (aged five and older) with sickle cell disease. The company also collaborates with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. Formerly known as Emmaus Holdings, Inc., the company changed its name to Emmaus Life Sciences, Inc. in September 2011, and it was founded in 2000, with its headquarters located in Torrance, California.
Emmaus Life Sciences, Inc. traces its origin back to the year 2000 when it was founded in the United States. The company was initially established as Emmaus Holdings, Inc. with the vision of developing and commercializing innovative treatments and therapies for rare and orphan diseases. The company's early focus was on conducting research and development to identify potential solutions for diseases with limited treatment options, particularly those affecting a small number of individuals, which are classified as rare or orphan diseases.
Over the years, Emmaus Life Sciences worked on advancing its lead candidate, Endari, an L-glutamine oral powder. Endari was specifically designed to reduce the acute complications of sickle cell disease in adult and pediatric patients aged five years and older. The development of this drug was a significant milestone for the company, as sickle cell disease is a rare and debilitating genetic disorder that affects a considerable number of individuals worldwide.
In September 2011, the company underwent a rebranding and changed its name to Emmaus Life Sciences, Inc., reflecting its transition from a research-focused entity to a commercial-stage biopharmaceutical company. Emmaus Life Sciences continued to advance its research and development efforts and garnered regulatory approvals for Endari, positioning itself as a prominent player in the field of rare disease treatments. The company also collaborated with Kainos Medicine, Inc. to work on the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug, further expanding its portfolio of potential treatments.